Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chia-Liang Liu

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Heart (British Cardiac Society)|April 16, 2021
Cost-effectiveness and affordability of novel cardiovascular therapies: what physicians need to knowEnrico Giuseppe Ferro, Chia-Liang Liu, Dhruv S Kazi
Current Cardiology Reports|October 2, 2021
The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical PracticeMerilyn S Varghese, Chia-Liang Liu, Dhruv S Kazi
BMC Bioinformatics|February 4, 2017
Multi-CAR: a tool of contig scaffolding using multiple referencesKun-Tze Chen, Cheih-Jung Chen, Hsin-Ting Shen, et al.
Bioinformatics (Oxford, England)|October 3, 2017
CSAR: a contig scaffolding tool using algebraic rearrangementsKun-Tze Chen, Chia-Liang Liu, Shang-Hao Huang, et al.
Circulation. Cardiovascular Quality and Outcomes|February 2, 2022
Cost-Effectiveness of Antibiotic-Eluting Envelope for Prevention of Cardiac Implantable Electronic Device Infections in Heart FailureRonuk M Modi, Chia-Liang Liu, Nicolas Isaza, et al.
JAMA Network Open|July 27, 2021
Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection FractionNicolas Isaza, Paola Calvachi, Inbar Raber, et al.
JAMA Cardiology|June 12, 2024
Climate Change and Cardiovascular Health: A Systematic ReviewDhruv S Kazi, Ethan Katznelson, Chia-Liang Liu, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Heart (British Cardiac Society)|April 16, 2021
Cost-effectiveness and affordability of novel cardiovascular therapies: what physicians need to knowEnrico Giuseppe Ferro, Chia-Liang Liu, Dhruv S Kazi
Current Cardiology Reports|October 2, 2021
The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical PracticeMerilyn S Varghese, Chia-Liang Liu, Dhruv S Kazi
BMC Bioinformatics|February 4, 2017
Multi-CAR: a tool of contig scaffolding using multiple referencesKun-Tze Chen, Cheih-Jung Chen, Hsin-Ting Shen, et al.
Bioinformatics (Oxford, England)|October 3, 2017
CSAR: a contig scaffolding tool using algebraic rearrangementsKun-Tze Chen, Chia-Liang Liu, Shang-Hao Huang, et al.
Circulation. Cardiovascular Quality and Outcomes|February 2, 2022
Cost-Effectiveness of Antibiotic-Eluting Envelope for Prevention of Cardiac Implantable Electronic Device Infections in Heart FailureRonuk M Modi, Chia-Liang Liu, Nicolas Isaza, et al.
JAMA Network Open|July 27, 2021
Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection FractionNicolas Isaza, Paola Calvachi, Inbar Raber, et al.
JAMA Cardiology|June 12, 2024
Climate Change and Cardiovascular Health: A Systematic ReviewDhruv S Kazi, Ethan Katznelson, Chia-Liang Liu, et al.
Pageof 1